Tranilast
- Generic Name
- Tranilast
- Drug Type
- Small Molecule
- Chemical Formula
- C18H17NO5
- CAS Number
- 53902-12-8
- Unique Ingredient Identifier
- HVF50SMY6E
- Background
Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
- Indication
For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
• Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.
• Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes.
• A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.
EMA Grants Positive Opinion for Orphan Drug Designation to Nuformix's NXP002 for Idiopathic Pulmonary Fibrosis
• The European Medicine Agency's Committee for Orphan Medical Products has issued a positive opinion regarding Orphan Drug Designation for Nuformix's NXP002 (tranilast) in idiopathic pulmonary fibrosis.
• This regulatory milestone provides Nuformix with potential benefits including 10 years of market exclusivity and accelerated development support, strengthening the company's position for future licensing partnerships.
• Despite widening interim losses to £376,668 in the six months ended March 31, Nuformix remains focused on advancing its portfolio assets while maintaining tight cost control.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath